Elucid is a medical technology company, founded in 2013 and based in Boston. The firm specializes in AI-powered analysis of cardiovascular imaging, with a focus on atherosclerosis and coronary computed tomography angiography (CCTA). Its work aims to support the prevention of heart attacks and strokes through advanced diagnostic software.
The company's primary product is PlaqueIQ™, which is described as the first and only FDA-cleared, non-invasive plaque analysis software validated against ground-truth histology for plaque characterization. The validation against histological ground truth is a notable technical milestone for a diagnostic imaging tool.
Elucid has a team of 51 employees working at the intersection of artificial intelligence and cardiovascular medicine. The company operates within the healthcare and medical technology verticals, applying machine learning techniques to complex medical imaging data.
